Curelator

Curelator Inc. was founded in 2013 based on the belief that one-size-fits-all medicine was failing the majority of humans who were not “average”. This short-coming is most acutely observed in chronic diseases with episodic attacks such as migraine, IBS, epilepsy, depression where medications are therapeutically effective in only a minority of patients.
Curelator developed the first digital health platform using N=1 analytics to enable personalized measurement of therapeutic response and identification of disease modifying life-style factors. The Company’s first product is N1-Headache, which is indicated for migraine and is being used in multiple clinical studies. Based on our personalized outcomes measurement platform we are now developing a suite of individualized digital therapeutics solutions.